Stopped: the study was terminated due to the primary end point being met.
THRIVE is an observational study that will collect information on patients with UCDs. THRIVE will follow enrolled participants for up to 10 years. As an observational study, enrolled patients will not be required to make any additional office visits or take any medicine outside of normal care.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Mean Blood Ammonia Levels Over Time, by Last Known Ammonia-Scavenging Medication
Timeframe: 12 months prior to enrollment (retrospective), Baseline, Day 7 to 30, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36, Month 42, Month 48, Month 54, Month 60, Month 66, Month 72
Median Blood Ammonia Levels Over Time, by Last-Known Ammonia-Scavenging Medication
Timeframe: 12 months prior to enrollment (retrospective), Baseline, Day 7 to 30, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36, Month 42, Month 48, Month 54, Month 60, Month 66, Month 72
Percentage of Participants With Hyperammonemic Crisis (HAC) by Baseline Ammonia-Scavenging Medication, Retrospective Values
Timeframe: 12 months prior to enrollment (retrospective)
Percentage of Participants With Hyperammonemic Crisis (HAC), Post-Baseline by Last Known Ammonia-Scavenging Medication
Timeframe: From enrollment through the end of study (mean overall duration on study was 1187.7 days).
Number of Participants With Serious Adverse Events (SAEs)
Timeframe: From enrollment through the end of study (mean overall duration on study was 1187.7 days).